Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.41 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862655 | 0.86 | SRC (0.40) | DHODHRORC | |
| SCHEMBL2860785 | 0.84 | CSNK1E (0.40) | PTGER1CSNK1EADORA1KCNN4 | |
| SCHEMBL2867613 | 0.83 | ADORA2A (0.39) | PTGER1CSNK1EADORA1KDM4EALDH1A1 | |
| SCHEMBL2870394 | 0.80 | PTGER1 (0.43) | PTGER1DCLRE1BDHODHCSNK1EKDM4E | |
| SCHEMBL4151590 | 0.79 | NFE2L2 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL4151593 | 0.79 | NFE2L2 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL27536169 | 0.78 | HCRTR1 (0.35) | PTGER1CSNK1EADORA1KCNN4 | |
| SCHEMBL2862953 | 0.77 | MGLL (0.43) | ADORA1 | |
| SCHEMBL2855702 | 0.77 | CA12 (0.38) | — | |
| SCHEMBL2864978 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| CN-1300116-C | 1H-indazole compounds | EISAI CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1512987-A | Novel 1H-indazole compound | ������������ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | PTGER1 3143/4885DCLRE1B 4617/4885DHODH 4329/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | PTGER1 4240/4885DCLRE1B 4429/4885DHODH 3251/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | PTGER1 3143/4885DCLRE1B 4617/4885DHODH 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.